Evidence map›Paper›PMID 37124096›Full record

ArticleFrontiers in genome editing2023

Assessment of anti-HIV-1 guide RNA efficacy in cells containing the viral target sequence, corresponding gRNA, and CRISPR/Cas9.

Alexander G Allen, Cheng-Han Chung, Stephen D Worrell, Glad Nwaozo, Rebekah Madrid, Anthony R Mele, Will Dampier, Michael R Nonnemacher, Brian Wigdahl

Abstract read
In one paragraph

Article in Frontiers in genome editing, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Delivering CRISPR to the HIV-1 reservoirs.Frontiers in microbiology · 2024
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alexander G AllenDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States.
Cheng-Han ChungDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States.
Stephen D WorrellDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States.
Glad NwaozoDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States.
Rebekah MadridDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States.
Anthony R MeleDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States.
Will DampierDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States.
Michael R NonnemacherDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States.
Brian WigdahlDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States.

Funding

Viral Gene Editing and Bioinformatics Core for Institution # 269291P30MH092177 · NIMH · TEMPLE UNIV OF THE COMMONWEALTH · PI Ilker Kudret Sariyer · 2011 to 2026
$24.9M
Gene editing strategies to target HIV for elimination in periphery and brainR01MH110360 · NIMH · DREXEL UNIVERSITY · PI Ilker Kudret Sariyer, Brian Wigdahl · 2016 to 2026
$7.3M
Interdisciplinary And Translational Research Training In NeurohivT32MH079785 · NIMH · TEMPLE UNIV OF THE COMMONWEALTH · PI Kamel Khalili · 2008 to 2026
$5.4M
NIMH NIH HHS P30 MH092177NIMH NIH HHS R01 MH110360NIMH NIH HHS T32 MH079785
6 · The paper itself

Abstract

The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene editing system has been shown to be effective at inhibiting human immunodeficiency virus type 1 (HIV-1). Studies have not consistently used a trackable dual reporter system to determine what cells received the Cas9/gRNA to determine the overall knockdown of HIV. Some studies have used stably transduced cells under drug selection to accomplish this goal. Here a two-color system was used that allows tracking of viral protein expression and which cells received the CRISPR/Cas9 system. These experiments ensured that each gRNA used was a perfect match to the intended target to remove this variable. The data showed that gRNAs targeting the transactivation response element (TAR) region or other highly conserved regions of the HIV-1 genome were effective at stopping viral gene expression, with multiple assays demonstrating greater than 95 percent reduction. Conversely, gRNAs targeting conserved sites of the 5' portion of the U3 region were largely ineffective, demonstrating that the location of edits in the long terminal repeat (LTR) matter with respect to function. In addition, it was observed that a gRNA targeting Tat was effective in a T-cell model of HIV-1 latency. Taken together, these studies demonstrated gRNAs designed to highly conserved functional regions have near 100% efficacy

Indexed as

CRISPR/Cas9cure strategygene therapyguide RNAsHIV-1 reservoir

Identifiers

PMID37124096
PMCPMC10134072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.